Incidence of Precipitated Withdrawal during a Multisite Emergency Department-Initiated Buprenorphine Clinical Trial in the Era of Fentanyl

Gail D'Onofrio; Kathryn F. Hawk; Jeanmarie Perrone; Sharon L. Walsh; Michelle R. Lofwall; David A. Fiellin; Andrew Herring

doi:10.1001/jamanetworkopen.2023.6108

Incidence of Precipitated Withdrawal during a Multisite Emergency Department-Initiated Buprenorphine Clinical Trial in the Era of Fentanyl

Gail D'Onofrio
, Kathryn F. Hawk
, Jeanmarie Perrone
, Sharon L. Walsh
, Michelle R. Lofwall
, David A. Fiellin
, Andrew Herring

Research output: Contribution to journal › Article › peer-review

56 Scopus citations

Original language	English
Pages (from-to)	E236108
Journal	JAMA network open
Volume	6
Issue number	3
DOIs	https://doi.org/10.1001/jamanetworkopen.2023.6108
State	Published - Mar 30 2023

Bibliographical note

Funding Information:
Funding/Support: This research was supported by the NIH through the NIH HEAL Initiative under award number UG1DA015831-18S7. Support by the NIDA CTN Data and Statistics Center was provided by the NIDA under contracts 271201500065C, 75N95020D00012, and 75N95019D00013.

Funding Information:
Conflict of Interest Disclosures: Dr D’Onofrio reported receiving grants from the National Institutes of Health (NIH) National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN) during the conduct of the study. Dr Hawk reported receiving grants from NIDA CTN during the conduct of the study. Dr Walsh reported receiving personal fees from Astra Zeneca, Cerevel, and Titan outside the submitted work. Dr Lofwall reported serving as a consultant to Journey Colab Scientific, advising on medications in development for non–opioid use disorder indications outside the submitted work. Dr Fiellin reported grants from NIDA during the conduct of the study. No other disclosures were reported.

Funding

Funding/Support: This research was supported by the NIH through the NIH HEAL Initiative under award number UG1DA015831-18S7. Support by the NIDA CTN Data and Statistics Center was provided by the NIDA under contracts 271201500065C, 75N95020D00012, and 75N95019D00013. Conflict of Interest Disclosures: Dr D’Onofrio reported receiving grants from the National Institutes of Health (NIH) National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN) during the conduct of the study. Dr Hawk reported receiving grants from NIDA CTN during the conduct of the study. Dr Walsh reported receiving personal fees from Astra Zeneca, Cerevel, and Titan outside the submitted work. Dr Lofwall reported serving as a consultant to Journey Colab Scientific, advising on medications in development for non–opioid use disorder indications outside the submitted work. Dr Fiellin reported grants from NIDA during the conduct of the study. No other disclosures were reported.

Funders	Funder number
National Institutes of Health (NIH)	UG1DA015831-18S7
National Institutes of Health (NIH)
Author National Institute on Drug Abuse DA031791 Mark J Ferris National Institute on Drug Abuse DA006634 Mark J Ferris National Institute on Alcohol Abuse and Alcoholism AA026117 Mark J Ferris National Institute on Alcohol Abuse and Alcoholism AA028162 Elizabeth G Pitts National Institute of General Medical Sciences GM102773 Elizabeth G Pitts Peter McManus Charitable Trust Mark J Ferris National Institute on Drug Abuse

ASJC Scopus subject areas

General Medicine

Access to Document

10.1001/jamanetworkopen.2023.6108

Cite this

@article{604bb3a4001b40969f2bd4cfd7f14ac9,

title = "Incidence of Precipitated Withdrawal during a Multisite Emergency Department-Initiated Buprenorphine Clinical Trial in the Era of Fentanyl",

author = "Gail D'Onofrio and Hawk, \{Kathryn F.\} and Jeanmarie Perrone and Walsh, \{Sharon L.\} and Lofwall, \{Michelle R.\} and Fiellin, \{David A.\} and Andrew Herring",

note = "Funding Information: Funding/Support: This research was supported by the NIH through the NIH HEAL Initiative under award number UG1DA015831-18S7. Support by the NIDA CTN Data and Statistics Center was provided by the NIDA under contracts 271201500065C, 75N95020D00012, and 75N95019D00013. Funding Information: Conflict of Interest Disclosures: Dr D{\textquoteright}Onofrio reported receiving grants from the National Institutes of Health (NIH) National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN) during the conduct of the study. Dr Hawk reported receiving grants from NIDA CTN during the conduct of the study. Dr Walsh reported receiving personal fees from Astra Zeneca, Cerevel, and Titan outside the submitted work. Dr Lofwall reported serving as a consultant to Journey Colab Scientific, advising on medications in development for non–opioid use disorder indications outside the submitted work. Dr Fiellin reported grants from NIDA during the conduct of the study. No other disclosures were reported. ",

year = "2023",

month = mar,

day = "30",

doi = "10.1001/jamanetworkopen.2023.6108",

language = "English",

volume = "6",

pages = "E236108",

number = "3",

}

TY - JOUR

T1 - Incidence of Precipitated Withdrawal during a Multisite Emergency Department-Initiated Buprenorphine Clinical Trial in the Era of Fentanyl

AU - D'Onofrio, Gail

AU - Hawk, Kathryn F.

AU - Perrone, Jeanmarie

AU - Walsh, Sharon L.

AU - Lofwall, Michelle R.

AU - Fiellin, David A.

AU - Herring, Andrew

N1 - Funding Information: Funding/Support: This research was supported by the NIH through the NIH HEAL Initiative under award number UG1DA015831-18S7. Support by the NIDA CTN Data and Statistics Center was provided by the NIDA under contracts 271201500065C, 75N95020D00012, and 75N95019D00013. Funding Information: Conflict of Interest Disclosures: Dr D’Onofrio reported receiving grants from the National Institutes of Health (NIH) National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN) during the conduct of the study. Dr Hawk reported receiving grants from NIDA CTN during the conduct of the study. Dr Walsh reported receiving personal fees from Astra Zeneca, Cerevel, and Titan outside the submitted work. Dr Lofwall reported serving as a consultant to Journey Colab Scientific, advising on medications in development for non–opioid use disorder indications outside the submitted work. Dr Fiellin reported grants from NIDA during the conduct of the study. No other disclosures were reported.

PY - 2023/3/30

Y1 - 2023/3/30

UR - https://www.scopus.com/pages/publications/85151532661

UR - https://www.scopus.com/pages/publications/85151532661#tab=citedBy

U2 - 10.1001/jamanetworkopen.2023.6108

DO - 10.1001/jamanetworkopen.2023.6108

M3 - Article

C2 - 36995717

AN - SCOPUS:85151532661

VL - 6

SP - E236108

JO - JAMA network open

JF - JAMA network open

IS - 3

ER -

Incidence of Precipitated Withdrawal during a Multisite Emergency Department-Initiated Buprenorphine Clinical Trial in the Era of Fentanyl

Bibliographical note

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this